Recently, Shenzhen Concemed Medical Technology Co., Ltd. (hereinafter referred to as "Concemed") completed tens of millions of yuan in Pre-A round financing, led by Tongchuang Weiye and followed by the National High Performance Medical Device Innovation Center (hereinafter referred to as "Guochuang Center"). The funds raised in this round will be invested in further consolidating and expanding the R&D pipeline, accelerating productization, and increasing brand market investment.

Founded in 2022, Concemed focuses on soft electronic endoscope products for gastroenterology. The company is committed to exploring clinical needs, creating high-quality products, and providing the best diagnostic and treatment solutions for clinical users. The Concemed team has rich experience in product research and production, and has built a comprehensive underlying technology reserve around the digestive science soft electronic endoscope platform. It can achieve deep self-developed and self-made mainframe and endoscope body, and its new technical solutions cover dozens of patented technologies. At present, Concemed has independently developed the first integrated soft endoscope platform in China, as well as innovative gastroscopy and colonoscopy products, and has laid out multiple innovative products around the soft endoscope platform.

According to the latest global cancer burden data in 2020 released by the International Agency for Research on Cancer (IARCa) of the World Health Organization, among the top ten cancer diseases with incidence rate in China, colorectal cancer, gastric cancer and esophageal cancer ranked second, third and sixth respectively. The incidence rate and mortality rate of malignant tumors increase with age, rising rapidly from the age of 40. With the aging of China, the incidence rate rate of digestive tract cancer is increasing.

At present, soft electronic endoscopes are still the most important screening and treatment equipment for digestive tract cancers. Early intervention, early detection, and early treatment of gastrointestinal precancerous diseases and tumors have gradually become a consensus. Endoscopic biopsy or pathological examination of resected specimens is the gold standard for the diagnosis of digestive tract cancer. Endoscopic resection of precancerous lesions can reduce the incidence rate and mortality of digestive tract cancer.

However, according to the bidding data of China Medical Procurement Network in 2021, the market share of domestic brands in the endoscope field is less than 10%, and domestic hospitals are still dominated by imported brands. Domestic manufacturers still urgently need breakthroughs in specialized technical fields such as endoscope body technology, duodenoscopy, 4K soft endoscope, optical magnifying glass, and ultrasonic endoscope. According to research data from CITIC Securities, the domestic market capacity of soft mirror equipment is growing rapidly, and it is expected to reach a scale of 8.12 billion by 2025 and 11 billion by 2030.

As China's aging population continues to deepen, the demand for early screening, diagnosis, and treatment of digestive tract cancers will also increase. Domestic brands of soft mirror instruments closely related to this will become a hot topic of industry and market attention. At the same time, as a serious medical product that combines diagnostic and therapeutic functions, users attach great importance to the safety and effectiveness of the soft mirror. Companies like Concemed, which have accumulated years of experience in medical device industrialization and can grasp technological innovation while ensuring product quality and stability, will be more favored by the market.

Ms. Huang Li, founding partner of Tongchuang Weiye, said: "Soft mirror products have a market size of billions, with many innovative techniques and a localization rate of only 10%. The market share is still monopolized by imported brands such as Olympus, making it a highly potential high-quality sub track in the medical device field. Our team has been paying attention to this track for a long time and has always hoped to find a team that can truly master the core technology and process know-how and make high-quality products. The Concemed team has long-term technical accumulation and research and development experience in this field, and they have successfully developed multiple excellent products that have been verified by top domestic and international hospitals. We believe that the team can create better high-end endoscopes and achieve further breakthroughs in innovative directions, becoming a leading comprehensive solution provider in the field of soft endoscopes, creating huge value for clinical fields such as gastroenterology, and benefiting patients more

Dr. Liu Heng, Deputy General Manager of the National Innovation Center, said, "The breakthrough of Concemed endoscope products is an innovative case in the field of domestic high-end medical devices. The Concemed team not only has the innovative transformation ability of excellent scientists and engineers, but also has the resilience and mature management philosophy of excellent entrepreneurs. The National Innovation Center is honored to participate in Concemed financing, and soft mirrors are also a key research direction of the National Innovation Center. This investment is an important measure for the National Innovation Center's layout in the field of soft mirrors, which will deepen the cooperation between the National Innovation Center and Concemed in technology research, product development, clinical applications, etc., improve the localization rate of soft mirrors, and break the monopoly of foreign giants

The Concemed team expresses gratitude for the support of new and old shareholders such as Tongchuang Weiye and Guochuang Center. Concemed will continue to actively respond to clinical needs, develop more innovative soft endoscope products, and strive to become a leading domestic and world-class provider of overall soft endoscope solutions

Shenzhen Tongchuang Weiye Asset Management Co., Ltd. (referred to as "Tongchuang Weiye") was established on June 26, 2000, and is one of the first local professional venture capital institutions in China. The company has over 22 years of investment management experience, managing over 30 billion RMB and investing in more than 600 companies. Over 100 companies have gone public, including 24 listed on the Science and Technology Innovation Board. It is a leading local brand professional investment institution in China with a long operating time and sustained excellent returns.

Tongchuang Weiye takes industrial chain investment as the entry point, focuses on emerging industries, and specializes in sub sectors such as big health, big technology, big information, and big consumption. It has accumulated rich investment experience in hard core technology and cutting-edge technology fields, deeply explores hidden champions with a stable investment strategy, and supports innovation and entrepreneurship with empowering investment, fully serving the real economy. Tongchuang Weiye adheres to the concept of "being a companion of entrepreneurial enterprises and a guide of great enterprises", and is committed to advancing and growing together with entrepreneurs and entrepreneurs with an open attitude, becoming a "super partner" of the enterprise.

The National High Performance Medical Device Innovation Center (hereinafter referred to as the "National Innovation Center") is led by the Chinese Academy of Sciences Shenzhen Advanced Technology Research Institute, Shenzhen Mindray Biomedical Electronics Co., Ltd., Shanghai Lianying Medical Technology Co., Ltd., Pioneer Technology (Shenzhen) Co., Ltd., Harbin Institute of Technology and other units. It was approved by the Ministry of Industry and Information Technology to build in April 2020. It is the first national manufacturing innovation center in Shenzhen and the only innovation center set up by the country in the field of medical devices.

The National Innovation Center focuses on the significant demand for high-end medical equipment in the fields of prevention, diagnosis, treatment, and rehabilitation closely related to medical health. It focuses on key areas such as high-end medical imaging, in vitro diagnosis and vital sign monitoring, advanced treatment, interventional devices, rehabilitation and health information, and is committed to breaking through the common core key technologies of industry development, completing technology development, transfer and diffusion to various links of first commercial application, and creating a high-performance medical device industry innovation ecosystem that runs through the innovation chain, industry chain, and capital chain.